Black Diamond Therapeutics, Inc.
BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The cā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.15
Price-1.83%
-$0.04
1Y
Price
Market Cap
$123.199m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$43.211m
-293.2%
1y CAGR-48.5%
3y CAGR-34.0%
5y CAGREPS
-$0.76
-294.9%
1y CAGR-43.9%
3y CAGR-26.6%
5y CAGRBook Value
$104.300m
$132.922m
Assets$28.622m
Liabilities$17.882m
DebtDebt to Assets
13.4%
-0.5x
Debt to EBITDAFree Cash Flow
-$34.028m
-214.9%
1y CAGR-20.2%
3y CAGR-9.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company